Similia Vol 34 No 2 – December 2021

Authors: Kate Birch, RSHom (NA), CCH, C HP; Jiuan Heng, CCH, RSHom (NA), C HP; Crystal Morse, BCN, DNM, C HP; Shelly Garrison, CCH, C HP; Cheryl Wood, CCH, RSHom (NA), C HP; Gabriella Calvi-Rooney, B S, DSH, C HP; Ursula Dobelmann, CCH, C HP

Abstract

Introduction

Homeopathic nosodes have been used historically for treatment and prevention of infectious disease. At the outset of the 2020 global pandemic with SARS CoV-2, we undertook to determine the longitudinal safety, efficacy and effects of dosing with Novus-CV. Through the homeopathic proving  process, a comprehensive Materia Medica was to be established. Once collated, practitioners would have an accurate symptom picture upon which to
prescribe.

Methods

Registrants of all age groups, from pregnant women and children to the elderly, undertook a self-administered dosing schedule of Novus-CV. All registrants satisfied an inclusion and exclusion criteria and informed consent process. Intake and follow-up forms detailed immunological status at  registration, during and after the trial period: previous and existent symptoms, elicited symptoms, and cured symptoms. All participants were to take a  single dose of Novus-CV 1M followed a week later by a triple dose (three times in one day: morning, noon, and evening), repeating the triple dose  upon known exposure.

Results

Registration took place from 1 February through 25 April 2020. Of the 803 two-week respondents who took the remedy 314 developed and/or  resolved one or more short-lived, immunological symptom similar to Covid-19: fever, body aches, sinus issues, cough, difficulty breathing, and other  general symptoms. Of the 63 registrants with active disease upon registration, the nosode resolved all condition symptoms. 313 respondents indicated either onset or, change in or resolution of symptoms. A total of 2741 symptoms were tabulated. Proving responses included mild, short-lived, and resolution of, acute immunological symptoms and mental and emotional experiences relating to the substance.

Conclusions

Homeopathic provings can stimulate short-lived symptoms relative to the agent studied. The cured and proving symptoms elicited through this study  revealed a comprehensive materia medica detailing the homeopathic indications of Novus-CV to be used in clinical practice or active cases.